A large new analysis has found that women who used estrogen-only menopausal hormone therapy showed fewer of the brain changes associated with Alzheimer’s disease, both in clinical records and in autopsy tissue. The study drew on data from more than 21,000 women and adds to a decades-long, unresolved scientific debate over whether estrogen protects the aging brain. Its authors were careful to stress that the results show an association, not proof that hormone therapy prevents dementia.
An analysis of more than 21,000 women
Researchers examined data from 21,462 women, combining clinical dementia diagnoses with detailed examinations of donated brain tissue. Women who reported using estrogen-only hormone therapy had 39% lower odds of a clinical dementia diagnosis and 35% lower odds of Alzheimer’s pathology at autopsy, compared with women who reported no hormone therapy of any kind. The autopsy comparison scored the amount and location of amyloid plaques and tau tangles, the two hallmark protein abnormalities of Alzheimer’s disease, along with plaque density.
The pathology portion of the work compared 258 brains of women who reported estrogen-only therapy against roughly 2,701 brains of women who reported never using hormone therapy. Users of estrogen-only therapy also showed biomarker profiles consistent with less amyloid accumulation. Because the analysis linked what women reported taking during life with what pathologists later found in their brain tissue, it offered a more direct look at the disease process than diagnosis records alone.
Estrogen-only versus combined hormone therapy
The distinction between estrogen-only and combined therapy is central to the findings. Combined menopausal hormone therapy pairs estrogen with a progestogen, which is added to protect the uterine lining in women who have not had a hysterectomy. Estrogen-only therapy is generally prescribed for women who have had a hysterectomy and therefore do not need that protection. Earlier research, most prominently the Women’s Health Initiative, complicated the picture by finding that a particular combined regimen begun in older women was associated with higher, not lower, dementia risk, which is part of why the field remains contested.
Estrogen itself is a steroid hormone with wide-ranging effects on the body, including on brain regions involved in memory. According to the National Institute on Aging, Alzheimer’s disease is characterized by the buildup of amyloid plaques and tau tangles that disrupt communication between neurons and eventually kill brain cells. The idea that estrogen might blunt that process has motivated researchers for years, but clinical trials and observational studies have produced conflicting results.
Why the study cannot prove cause and effect
The authors and independent commentators emphasized that the analysis was observational and cannot establish that hormone therapy prevents dementia. Women who choose or are prescribed hormone therapy may differ in other ways, such as overall health, access to care or lifestyle, that independently affect brain aging. Those differences can create the appearance of a protective effect even where none exists, a persistent challenge in this area of research.
A further caveat concerns timing. The participants who used hormone therapy in this analysis had an average age of about 70, whereas current clinical practice usually starts hormone therapy in the late 40s to early 50s, around menopause, and stops it before age 60. That gap matters because of what researchers call the “timing hypothesis,” the idea that estrogen’s effect on the brain and blood vessels may depend heavily on when in life it is taken. Findings drawn from women who took estrogen later in life may not translate directly to younger women following today’s prescribing patterns.
Where the finding fits a contested field
The new results arrive in a research landscape marked by decades of back-and-forth. Some observational studies have linked estrogen use to lower dementia risk, while major randomized trials have failed to confirm a protective effect and, in some cases, suggested harm from specific regimens started later in life. Reporting on the current study noted that it was published in Neurology, the medical journal of the American Academy of Neurology, and that its combination of clinical and autopsy data was a notable strength, even though it shares the fundamental limitation of all observational work.
What sets the analysis apart is the pathology evidence. Rather than relying only on whether women were diagnosed with dementia, the researchers could examine the physical signatures of Alzheimer’s in brain tissue, an approach that reduces the risk of misclassification and provides a biological correlate for the clinical association. The consistency between fewer diagnoses and fewer autopsy hallmarks strengthens, without proving, the case that estrogen-only therapy and reduced Alzheimer’s pathology are genuinely linked.
What it means for women weighing hormone therapy
For women and their clinicians, the study does not change the standard reasons hormone therapy is prescribed, which center on relieving menopausal symptoms such as hot flashes and on bone health, not on preventing dementia. Medical guidance continues to weigh benefits against risks, including cardiovascular and cancer considerations that vary by regimen, age and individual history. Independent coverage of the research made the same point, noting that the results cannot show cause and should not be read as a recommendation to take estrogen for brain protection.
The more durable contribution of the analysis may be to sharpen the questions researchers pursue next: which formulations, at which ages, and through which biological pathways might influence the accumulation of amyloid and tau. Answering those questions will require the kind of controlled trials that observational data, however large, cannot replace. For now, the finding stands as a substantial piece of evidence pointing toward a link, and an equally clear reminder of how much remains unsettled about estrogen and the aging brain.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
